Filing Details

Accession Number:
0001166279-13-000001
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-09-11 20:34:01
Reporting Period:
2013-09-10
Filing Date:
2013-09-11
Accepted Time:
2013-09-11 20:34:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1080709 Arena Pharmaceuticals Inc ARNA Pharmaceutical Preparations (2834) 232908305
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1166279 P Dominic Behan C/O Arena Pharmaceuticals, Inc.
6154 Nancy Ridge Drive
San Diego CA 92121
Evp & Chief Scientific Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-09-10 150,000 $1.49 603,000 No 4 M Direct
Common Stock Acquisiton 2013-09-10 50,000 $1.81 653,000 No 4 M Direct
Common Stock Disposition 2013-09-10 200,000 $6.31 453,000 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2013-09-10 150,000 $0.00 150,000 $1.49
Common Stock Employee Stock Option (right to buy) Disposition 2013-09-10 50,000 $0.00 50,000 $1.81
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
150,000 2021-03-15 No 4 M Direct
450,000 2022-03-19 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. This price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $6.26 and $6.34 per share, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  3. The options vest in four equal annual installments, and are exercisable once vested. The first and second installments became exercisable on March 15, 2012, and 2013, and the third and fourth installments vest on March 15, 2014, and 2015.
  4. The options vest in four equal annual installments, and are exercisable once vested. The first installment became exercisable on March 19, 2013, and the second, third and fourth installments vest on March 19, 2014, 2015 and 2016.